Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Urol. doi: /nrurol

Published byŌΓώγ Παπάζογλου Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Urol. doi: /nrurol"— Presentation transcript:

1 Nat. Rev. Urol. doi:10.1038/nrurol.2017.163
Figure 2 Post hoc analysis of data from patients with stage II or III intermediate-risk, nonstromal, nonepithelial Wilms tumour in the SIOP−2001 randomized controlled trial Figure 2 | Post hoc analysis of data from patients with stage II or III intermediate-risk, nonstromal, nonepithelial Wilms tumour in the SIOP−2001 randomized controlled trial. Association of tumour volume with a | event-free survival (EFS) and b | overall survival (OS). Kaplan Meier curves. van den Heuvel-Eibrink, M. M. et al. (2017) Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol Nat. Rev. Urol. doi: /nrurol

Download ppt "Nat. Rev. Urol. doi: /nrurol"

Similar presentations

Oncol Res Treat 2016;39: DOI: /

Oncol Res Treat 2016;39: DOI: /
Harrison CN et al. Proc ASH 2015;Abstract 59.

Harrison CN et al. Proc ASH 2015;Abstract 59.
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 1 Male infertility and assisted reproduction globally

Figure 1 Male infertility and assisted reproduction globally
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo

Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo
Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 3 Semantic model of the active surveillance (AS) timeline

Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Representative images from a right radical

Figure 2 Representative images from a right radical
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.
Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 The association between CD8+ T‑cell density of the tumour
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Similar presentations

Ads by Google